Recombinant factor VIIAa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors

British Journal of Haematology

Volumn 116, Issue 3, 2002, Pages 632-635

  Smith, Owen P ^a   Smith, Jude ^a   McMahon, Corrina ^a   O'Connell, Niamh ^a   Liesner, Ri ^b   Hann, Ian ^b   Khair, Kate ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Haemophilia; Inhibitors; Paediatrics; Recombinant factor VIIa; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 7A; FIBRIN GLUE; TRANEXAMIC ACID; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADOLESCENT; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SCREENING; HEMATOMA; HEMOPHILIA; HUMAN; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; TOOTH EXTRACTION; TREATMENT OUTCOME; ACUTE DISEASE; CLINICAL TRIAL; DRUG MONITORING; HEMOPHILIA A; HEMOSTASIS; INFANT; METHODOLOGY; MULTICENTER STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADOLESCENT; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS, SURGICAL; HUMANS; INFANT; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 0036008495     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2001.03324.x     Document Type: Article

References (21)

1. Central venous access catheters in children with haemophilia
2. The use of central venous catheters (portacaths) in children with haemophilia
3. NovoSeven in immune tolerance therapy
4. Complications experienced with central venous catheters in children with congenital bleeding disorders
5. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper
6. Immune tolerance: A synopsis of the international experience
7. Haemophilia. Treatment of patients with inhibitors: Cost issues
8. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophlila Centre Doctors' Organisation (UKHCDO)
9. Dosing and monitoring NovoSeven treatment
10. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
11. Activated factor VII activates FIX and FX on the surface of activated platelets: Thoughts on the mechanism of action of high dose activated factor VII
12. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa
13. Management and monitoring of recombinant activated factor VII
14. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 Years follow-up
15. Port-A-Cath usage in children with haemophilia: Experience of 53 cases
16. Clinical experience with recombinant factor VIIa
17. Low-dose immune tolerance induction in haemophilia A patients with inhibitors
18. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn protocol': Predictive parameter for therapy duration and outcome
19. Clinical experience with activated factor VII: Focus on safety aspects
20. Prospective randomised trial of two doses of rfVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery
21. rVIIa therapy to secure haemostasis during central line insertion in children with high responding factor VIII inhibitors